Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-06-26
2007-06-26
Devi, S. (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S139100, C424S130100, C424S134100, C424S803000, C424S163100, C424S164100, C424S137100, C530S387500, C530S387100, C530S389100, C514S008100
Reexamination Certificate
active
11375215
ABSTRACT:
A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived fromE. coliand purified outer membrane protein derived fromN. meningitidis. The same vaccine will also actively immunize a host subject against Gram-negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine.
REFERENCES:
patent: 4707543 (1987-11-01), Zollinger et al.
patent: 109688 (1984-05-01), None
patent: WO 8707148 (1987-12-01), None
Tarkka et al. Microbial Pathogenesis 3: 445-453, 1987.
Barlow et al. Infect. Immun. 55: 2734-2740, 1987.
Bhattacharjee, “Complex Vaccine with Neisseria . . . ”, 94thASM General Meeting, May 1994, p. 151.
Bhattacharjee, “Affinity PurifiedE. coli. . . ”, Clinical Research, 1993, 41:2.
Calandra et al., “Immunotherapy for Gram-Negative Septic Shock . . . ”, J. Infect. Dis., Aug. 1988, 158:2, pp. 312-319.
Cross et al., “The Efficacy of Combination . . . ”, Journal Infectious Diseases, Jan. 1993, 167:112-118.
Cross et al., “Therapeutic Intervention in Sepsis . . . ”, Journal Endotoxin Research, 1994, pp. 57-69.
Cryz, Jr. et al., “Synthesis, Character.Escherichia coli018 . . . ”, Infect. Immun., Feb. 1990, 58:2, pp. 373-377.
Cryz, Jr. et al., “Pseudomonas O-Antigen-Toxin A Vaccine . . . ”, Prevent. P. Aeruginosa Infect., 1989, 42:177-183.
Greenman et al., “E5 Antibody in Gram-Nagative Sepsis . . . ”, JAMA, Aug. 1991, 266:8, pp. 1097-1102.
Kanegasaki et al., “Comparison Biological Activities . . . ”, Bact. Endo. Chem., 1984, pp. 149-158.
Mandell et al., Infection and Immunity, 1989, 57:1590-1598.
Moreno et al., Infection and Immunity 1985, 47:527-533.
Ziegler et al., “Treatment Gram-Negative Bacteremia . . . ”, New Eng. J. of Med., Feb. 1991, 324:7, pp. 429-436.
Ziegler et al., “Treatment Gram-Negative Bacteremia . . . ”, New Eng. J. of Med., Nov. 1982, 307:1225-1230.
Ziegler et al., “Prevention Lethal Pseudomonas . . . ”, Trans. Am. Physiol., 1975, 88:101-108.
Ziegler et al., “Treatment ofE. coliand Klebsiella Bacteremia . . . ”, J. Immun. Aug. 1973, 112:2, pp. 433-438.
Bhattacharjee Apurba
Cross Alan
Sadoff Jerald
Zollinger Wendell
Arwine Elizabeth
Devi S.
United States of America as represented by the Secretary of the
LandOfFree
Vaccine against Gram-negative bacterial infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine against Gram-negative bacterial infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine against Gram-negative bacterial infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3881845